Comparative Pharmacology
Head-to-head clinical analysis: ESTRACE versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRACE versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
ESTRACE vs LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol, a form of estrogen, binds to and activates nuclear estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent physiological effects including development of secondary sexual characteristics, regulation of reproductive cycle, and effects on bone density, lipid metabolism, and cardiovascular system.
Combination hormonal contraceptive. Ethinyl estradiol and levonorgestrel inhibit gonadotropin release (FSH, LH), suppressing ovulation. Progestin effect: thickens cervical mucus, alters endometrial receptivity. Ferrous fumarate provides iron supplementation during placebo phase.
1 to 2 mg orally once daily for continuous estrogen replacement; 0.1% cream applied vaginally 1 to 2 times daily for atrophic vaginitis.
One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol, 75 mg ferrous fumarate) orally once daily at the same time for 21 consecutive days, followed by one ferrous fumarate-only tablet (75 mg) orally once daily for 7 days (28-day cycle).
None Documented
None Documented
Terminal half-life: 13-27 hours (mean 19 hours); clinical context: supports once-daily dosing for hormone replacement.
Levonorgestrel: ~25 hours, steady-state after 5 days. Ethinyl estradiol: ~13 hours (7–20). Ferrous fumarate: not applicable.
Renal: 50-80% as glucuronide and sulfate conjugates; fecal: 10-20%; biliary: minor (<5%).
Levonorgestrel: ~45% renal, ~32% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Ferrous fumarate: iron excreted in feces as unabsorbed; minimal renal.
Category C
Category D/X
Estrogen
Estrogen